- Third quarter revenues were $6.3 million - - 589 TranS1 procedures performed globally in the quarter - - Net loss per share was $0.18 for the quarter - - Excluding special items, net loss per share was $0.16 for the quarter* - WILMINGTON, N.C., Nov. 9, 2010 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region, today announced its financial results for the third quarter ended September 30, 2010.
|Comparison of Selected Financial Results (in millions, except per share data)|
|Three Months Ended Sept. 30,|
|Net loss per common share||(0.18)||(0.27)|
|Excluding special items*:|
|Net loss per common share||(0.16)||(0.23)|
|* See "Reconciliation of GAAP Financial Information to Non-GAAP Financial Information" below.|